Insight

Jun 28, 2024, 14:52

Iván R. González: ICIs in early-stage NSCLC showing promising results

Iván R. González, Medical Oncologist at Comprehensive Oncology Center, Hospital Ángeles Puebla, shared a post on X:

“The inhibition of immune checkpoint points in early-stage NSCLC treatment is showing promising results:

Immunotherapy combined with neoadjuvant chemotherapy significantly improves surgical outcomes and long-term survival.
The combination of immune checkpoint inhibitors and platinum-based chemotherapy is preferred over chemotherapy alone due to lower risk of surgical omission.
Despite advances, the 5-year survival rate remains suboptimal, with many patients experiencing relapse and death from metastatic progression.
Numerous questions persist regarding the optimal strategy, underscoring the need for further research.
Case-by-case discussions in multidisciplinary boards are crucial for addressing challenges and optimizing treatment strategies.

In conclusion immune checkpoint inhibition is transforming early-stage lung cancer treatment, enhancing outcomes and survival. While promising, additional research is needed to address remaining challenges and optimize clinical application.”

Read further.
Source: Iván R. González/X
.

cancer clinical research Comprehensive Oncology Center Hospital Ángeles Puebla Immune Checkpoint Inhibitors immunotherapy Iván R. González long-term survival medical oncologist multidisciplinary approach neoadjuvant chemotherapy non small cell lung cancer NSCLC OncoDaily Oncology platinum-based chemotherapy surgical outcomes Treatment optimization

Bernard Fox received SITC lifetime achievement award

Karen Knudsen: Better Together - Partnering to Accelerate Progress against Cancer

Sharon Osbourne and Colon Cancer: How She Went Against, How She Survived, and More

Marcia Cross and Anal Cancer: How She Went Against, How She Survived, and More

Pancreatic Cancer: Symptoms, Causes, Types, Diagnosis & Treatment

Special Coverage